[Federal Register Volume 63, Number 29 (Thursday, February 12, 1998)] [Notices] [Pages 7181-7182] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-3607] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Registration By Notice dated October 6, 1997, and published in the Federal Register on October 22, 1997, (62 FR 54857), Novartis Pharmaceuticals Corp., Attn: Compliance, 59 Route 10, East Hanover, 556 Morris Avenue, Summit, New Jersey 07901, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of methylphenidate (1724), a basic class of controlled substance listed in Schedule II. The firm plans to manufacture the finished product for distribution to its customers. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Novartis Pharmaceuticals Corp. to manufacture methylphenidate is consistent with the public interest at this time. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of [[Page 7182]] controlled substance listed above is granted. Dated: January 21, 1998. John H. King, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 98-3607 Filed 2-11-98; 8:45 am] BILLING CODE 4410-09-M